Spyre Therapeutics Inc <SYRE.O>: Baird assumes coverage with outperform rating; target price $120
SYRE•Related News
Nasdaq trade halt continues <GTBP.O> halt news pending at 03:28 AM
GTBP•
Roivant to present Phase 2 PHocus mosliciguat topline data in PH-ILD at ERS Congress Sept. 8, 2026
ROIV•
Nasdaq trade halt continues <UCFI.O> reason not available at 07:50 PM
UCFI•
Nasdaq trade halt continues <SFWL.O> halt news pending at 03:28 AM
SFWL•
Iran's Hormuz leverage wanes as US economic squeeze bites
XLE•